Requires manufacturers of radiological computer-assisted diagnostic software to disclose image analysis algorithm details, performance testing protocols and results, and software limitations.
Requires manufacturers of radiological computer-assisted diagnostic software to provide a detailed description of the image analysis algorithms including inputs, outputs, major components, and limitations.
Requires disclosure of pre-specified performance testing protocols used to assess whether the device will improve reader performance as intended.
Requires disclosure of results from performance testing that follows pre-specified protocols.
Requires manufacturers to provide appropriate software documentation including device hazard analysis, software design specs, traceability analysis, and cybersecurity features.
Mandates labeling that details compatible imaging hardware and imaging protocols, as well as the intended reading protocol.
Key facts
🏛️ This document has been enacted by the U.S. Food and Drug Administration.
For authoritative text and metadata, visit the official source.
🎯 This document primarily applies to the private sector, rather than the government.
📜 This document's name is 21 CFR § 892.2060 ("Radiological computer-assisted diagnostic software for lesions suspicious of cancer").
Themes
AI risks, applications, governance strategies, and other themes addressed in AGORA documents.
This tag applies to documents that address whether humans can understand (a) the mechanisms underlying an AI system’s operation and/or (b) the meaning of the systems’ output in the context of use.
This tag applies to documents that address the ability of an AI system to perform as required, without failure, under the conditions of expected use and over a given period of time, including the entire lifetime of the system.
This tag applies to documents that govern the security of digital systems associated with AI, including systems involved in development and training, systems housing related intellectual property, and computing infrastructure for deployed models.
This tag applies to documents that require, encourage, etc. the disclosure of information about AI systems by their users, developers, vendors, or others directly involved with the systems to third parties, including but not limited to the general public.
This tag applies to documents that require, encourage, etc. the systematic evaluation of AI systems, or of broader systems or processes into which AI is directly integrated.
This tag applies to documents that discuss evaluations that assess whether deployed AI systems meet the expectations specified or claimed prior to deployment.
This tag applies to documents that require or incentivize AI systems to incorporate specific features or achieve (or not achieve) specified results in operation, or to be used or not to be used in specified ways or for specific purposes. Requirements may be defined objectively (e.g., systems must score above a certain level on an established benchmark, systems must incorporate a certain technical feature) or subjectively (e.g., systems must not demonstrate undue bias).
This is an unofficial copy. The document has been
archived and reformatted in plaintext for AGORA. Footnotes, tables, and
similar material may be omitted. For the official text, visit the original source.
§ 892.2060 Radiological computer-assisted diagnostic software for lesions suspicious of cancer.
(a) Identification.
A radiological computer-assisted diagnostic software for lesions suspicious of cancer is an image processing prescription device intended to aid in the characterization of lesions as suspicious for cancer identified on acquired medical images such as magnetic resonance, mammography, radiography, or computed tomography. The device characterizes lesions based on features or information extracted from the images and provides information about the lesion(s) to the user. Diagnostic and patient management decisions are made by the clinical user.
Identifies software aiding in lesion characterization as suspicious for cancer on medical images.
Identifies software aiding in lesion characterization as suspicious for cancer on medical images.
(b) Classification.
Class II (special controls). The special controls for this device are:
(1) Design verification and validation must include:
(i) A detailed description of the image analysis algorithms including, but not limited to, a detailed description of the algorithm inputs and outputs, each major component or block, and algorithm limitations.
(ii) A detailed description of pre-specified performance testing protocols and dataset(s) used to assess whether the device will improve reader performance as intended.
(iii) Results from performance testing protocols that demonstrate that the device improves reader performance in the intended use population when used in accordance with the instructions for use. The performance assessment must be based on appropriate diagnostic accuracy measures (e.g., receiver operator characteristic plot, sensitivity, specificity, predictive value, and diagnostic likelihood ratio). The test dataset must contain sufficient numbers of cases from important cohorts (e.g., subsets defined by clinically relevant confounders, effect modifiers, concomitant diseases, and subsets defined by image acquisition characteristics) such that the performance estimates and confidence intervals of the device for these individual subsets can be characterized for the intended use population and imaging equipment.
(iv) Standalone performance testing protocols and results of the device.
(v) Appropriate software documentation (e.g., device hazard analysis; software requirements specification document; software design specification document; traceability analysis; and description of verification and validation activities including system level test protocol, pass/fail criteria, results, and cybersecurity).
Specifies design verification, performance testing, and software documentation for Class II device special controls.
Specifies design verification, performance testing, and software documentation for Class II device special controls.
(2) Labeling must include:
(i) A detailed description of the patient population for which the device is indicated for use.
(ii) A detailed description of the intended reading protocol.
(iii) A detailed description of the intended user and recommended user training.
(iv) A detailed description of the device inputs and outputs.
(v) A detailed description of compatible imaging hardware and imaging protocols.
(vi) Warnings, precautions, and limitations, including situations in which the device may fail or may not operate at its expected performance level (e.g., poor image quality or for certain subpopulations), as applicable.
(vii) Detailed instructions for use.
(viii) A detailed summary of the performance testing, including: Test methods, dataset characteristics, results, and a summary of sub-analyses on case distributions stratified by relevant confounders (e.g., lesion and organ characteristics, disease stages, and imaging equipment).
Requires labeling to include detailed descriptions, warnings, instructions, and performance testing summaries for the device.
Requires labeling to include detailed descriptions, warnings, instructions, and performance testing summaries for the device.